Characterize cell types, immune repertoires and mechanisms of immune evasion at the highest resolution.

Research into our complex and dynamic defense system benefits from the latest developments in genomic measurement technologies.
What are the key cell types that bring about an immune response? How do they develop? How do they malfunction in autoimmune diseases? And how can the immune system be leveraged to treat cancer? We apply advanced computational analyses to your high-throughput data to help answer questions like these.
Learn more about our expertise and some of the typical computational analyses in immunology, immunobiology and immuno-oncology below.

Discover cell types

Studying the composition and functions of the immune system often relies on transcriptomic and epigenomic sequencing.

We analyze RNA-sequencing, single-cell RNA-sequencing and single-cell ATAC sequencing data to

• identify, quantify and compare the types of immune cells in across developmental stages, niches and other conditions,
• characterize the intracellular pathways of immune cells in response to stimulation, and
• identify interactions between cells of the immune system and those between immune cells and other tissues.

Uncover host-pathogen interactions

RNA-sequencing of immune cells from pathogen-infected models, in vivo or vitro, allows for characterizing
the mechanisms in which the various cell types of the immune system react to antigens, rely information,
and neutralize pathogens.

LEARN MORE

Study tumor immune evasion

In cancer research, (single-cell) RNA-sequencing of tumors enables characterizing their immune microenvironments.
Identifying tumor-infiltrating immune cells helps studying the mechanisms and therapeutic opportunities of immune evasion.
Tumor RNA- or DNA-sequencing data can also be used to identify potential neo-antigens for cancer vaccine development.

Selected publications from our customers

1. Mezheyeuski, A. et al. (2023). An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers. EBioMedicine, 88, 104452. Advance online publication
   Click Here


2. Tusup, M. et al. (2022). Epitranscriptomics modifier * indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors. Molecular therapy : the journal of the American Society of Gene Therapy, 30(3), 1163–1170.
   Click Here


3. Cramer, M. et al. (2022). Transcriptomic Regulation of Macrophages by Matrix-Bound Nanovesicle-Associated Interleukin-33. Tissue engineering. Part A, 28(19-20), 867–878
   Click Here


4. Ribeiro, R. et al. (2022). Synchronous Epidermodysplasia Verruciformis and Intraepithelial Lesion of the Vulva is Caused by Coinfection with α-HPV and β-HPV Genotypes and Facilitated by Mutations in Cell-Mediated Immunity Genes. Preprint at
   Click Here


5. Wullt, B. et al. (2021). Immunomodulation-A Molecular Solution to Treating Patients with Severe Bladder Pain Syndrome?. European urology open science, 31, 49–58.
   Click Here


6. Åvall-Jääskeläinen, S. et al. (2021). Genomic Analysis of Staphylococcus aureus Isolates Associated With Peracute Non-gangrenous or Gangrenous Mastitis and Comparison With Other Mastitis-Associated Staphylococcus aureus Isolates. Frontiers in microbiology, 12, 688819.
   Click Here


7. Madonna, G. et al. (2021). Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Cancers, 13(16), 4164.
   Click Here


8. Gurvich, O. L. et al. (2020). Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products. Scientific reports, 10(1), 14049.
   Click Here


9. Oksanen, M. et al. (2020). NF-E2-related factor 2 activation boosts antioxidant defenses and ameliorates inflammatory and amyloid properties in human Presenilin-1 mutated Alzheimer's disease astrocytes. Glia, 68(3), 589–599.
   Click Here